Peptides for Immune system
The peptides people most often research for immune system, with how much evidence exists for each. A long list does not mean any of them is proven to work in people.
- Peptides listed
- 4
- With human trials
- 1
- FDA approved (any use)
- 0
- Thymosin Alpha-1Immune modulatorHuman RCT evidence, 4 of 4BMJ 2025, PMID 39814420Human222Animal101Summarised10Not FDA approved · approved abroadFor immune systemOverview
- BPC-157Gastric pentadecapeptideNo study with an outcome for immune systemPubMed search, 11 Oct 2026Human0Animal1Summarised0PCAC voted 8–6 for 503A (Jul 2026)Overview
- TB-500Synthetic fragment of thymosin beta-4No study with an outcome for immune systemPubMed search, 11 Oct 2026Human27Animal37Summarised0PCAC voted 8–6 for 503A (Jul 2026)Overview
- KPVAnti-inflammatory tripeptideNo study with an outcome for immune systemPubMed search, 11 Oct 2026Human2Animal3Summarised0PCAC voted 8–6 for 503A (Jul 2026)Overview
What this list does not show
Search demand tells you what people are curious about, not what works. Read each peptide's evidence before anything else.
Search interest is not evidence
This list follows what people search for and discuss. It says nothing about how well any peptide works.Animal results may not carry over
Doses, routes and effects seen in rodents or cell dishes often have no tested human equivalent.Approval covers specific uses
An FDA approval applies to the conditions and doses on the label, not to every goal a drug is searched with.Combinations are a separate question
Blends and stacks put several peptides together. Evidence for one peptide is not evidence for the mix.What the immune system is
MedlinePlus describes the immune system as a network of cells, tissues and organs that helps the body fight infections and other diseases.[25]
Which listed peptides have human data and what it shows
PubMed records matching the site's immune search: thymosin alpha-1 222 human-only and 101 animal-only; BPC-157 0 human-only and 1 animal-only; TB-500 27 human-only and 37 animal-only; KPV 2 human-only and 3 animal-only.
Calculated from goal immune-system; ledger date 2026-10-02; counts thymosin-alpha-1 (human only 222, animal 101, rct 42), bpc-157 (human only 0, animal 1, rct 0), tb-500 (human only 27, animal 37, rct 0), kpv (human only 2, animal 3, rct 0). Formula: Copied from web/src/data/goals.json: peptides[].ledger.humanOnly.n and ledger.animal.n for this goal (PubMed title/abstract search, humans[mh] NOT animals vs animals NOT humans).
The largest randomized trial of thymosin alpha 1 cited here was in sepsis patients. 28 day all-cause mortality was 23.4% on thymosin α1 and 24.1% on placebo.[1]
Pooling all sepsis trials produced a lower mortality estimate, but the same meta-analysis found no mortality benefit in its high-quality and multicentre subgroups.[26]
In a cohort study, the increase in CD4+ and CD8+ T cell counts during recovery did not differ significantly between patients with and without Tα1 therapy.[27]
Common questions
Do peptides boost the immune system?
Thymosin alpha 1 was tested in sepsis rather than in healthy people. In the large randomized trial, no secondary or safety outcome differed statistically significantly between the groups.[1]
Is thymosin alpha 1 proven to work for immunity?
A meta-analysis reported that thymosin-α1 may reduce all-cause mortality (RR 0.53), and rated the evidence as very low-certainty.[28]
Explore nearby goals
Sources
- 1The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial.BMJ (Clinical research ed.) · 2025PMID 39814420Accessed 2 Oct 2026
- 2PubMed search: "BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab] OR "pentadecapeptide BPC"[tiab] (230 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 3PubMed search: ("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (7 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 4PubMed search: "BPC-157"[tiab] AND humans[mh] (52 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 5PubMed search: ("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab] OR "pentadecapeptide BPC"[tiab]) AND (patients[tiab] OR clinical trial[pt] OR randomized[tiab]) (25 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 6PubMed search: ("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab] OR "pentadecapeptide BPC"[tiab]) AND (colitis[tiab] OR inflammatory bowel[tiab]) (48 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 7PubMed search: ("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab] OR "pentadecapeptide BPC"[tiab]) AND (tendon[tiab] OR ligament[tiab] OR muscle[tiab] OR bone[tiab] OR arthritis[tiab]) (58 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 8PubMed search: ("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab] OR "pentadecapeptide BPC"[tiab]) AND (nerve[tiab] OR neuropath*[tiab] OR spinal[tiab] OR liver[tiab] OR wound[tiab] OR burn[tiab]) (90 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 9PubMed search: ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab]) (1199 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 10PubMed search: ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab]) AND (humans[mh] OR patients[tiab]) (678 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 11PubMed search: ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab]) AND (randomized[tiab] OR clinical trial[pt]) (18 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 12PubMed search: ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (16 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 13PubMed search: ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab]) AND (wound[tiab] OR dermal[tiab] OR skin[tiab] OR hair[tiab]) (212 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 14PubMed search: ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab]) AND (tendon[tiab] OR muscle[tiab] OR cardiac[tiab] OR myocardial[tiab] OR heart[tiab]) (246 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 15PubMed search: "TB-500"[tiab] OR TB500[tiab] OR "Ac-LKKTETQ"[tiab] (33 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 16PubMed search: (KPV[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab]) (132 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 17PubMed search: (KPV[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab]) AND (alpha-MSH[tiab] OR melanocortin[tiab] OR colitis[tiab] OR inflammat*[tiab]) (95 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 18PubMed search: (KPV[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 19PubMed search: (KPV[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab]) AND (clinical trial[pt] OR randomized[tiab] OR patients[tiab]) (9 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 20PubMed search: ("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (57 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 21PubMed search: ("BPC-157"[tiab] OR "BPC 157"[tiab]) AND (human[tiab] OR patient*[tiab] OR volunteer*[tiab]) AND (adverse[tiab] OR safety[tiab] OR "side effects"[tiab]) (19 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 22PubMed search: ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab] OR RGN-259[tiab] OR RGN-137[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (61 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 23PubMed search: ("RGN-259"[tiab] OR "RGN-137"[tiab] OR "thymosin beta 4"[tiab]) AND (eye[tiab] OR ophthalmic[tiab] OR neurotrophic[tiab] OR cornea*[tiab]) AND (patients[tiab] OR trial[tiab]) (15 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 24PubMed search: (KPV[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (8 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 25Official web pageOfficial web page · web page
- 26Efficacy of thymosin α1 for sepsis: a systematic review and meta-analysis of randomized controlled trials.Frontiers in cellular and infection microbiology · 2025PMID 40969554Accessed 2 Oct 2026
- 27Thymosin Alpha-1 Has no Beneficial Effect on Restoring CD4+ and CD8+ T Lymphocyte Counts in COVID-19 Patients.Frontiers in immunology · 2021PMID 34149679Accessed 2 Oct 2026
- 28Thymosin-ɑ1 for people with chronic hepatitis B.The Cochrane database of systematic reviews · 2026PMID 42713852Accessed 2 Oct 2026
Found an error? Report a correction.